Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02317627 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
A Phase 2 study, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT02317627 is a Phase 2 study that has completed, run by Kadmon Corporation. The registered enrollment target is 38 participants.
The verdict
NCT02317627, a Phase 2 study, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one line of systemic therapy.
Interventions
- DRUG KD025
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02317627
The ClinicalTrials.gov registry entry for NCT02317627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KD025 is the first listed.
NCT02317627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02317627 about?
NCT02317627 is a clinical study titled "Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy". This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one line of systemic therapy.
What is the current status of trial NCT02317627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2014-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02317627?
The interventions under investigation include: KD025 (DRUG).
Who is sponsoring clinical trial NCT02317627?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.